テキサスにおける神経内分泌腫瘍の臨床試験
テキサス内の拠点で、神経内分泌腫瘍に関する11件の研究が参加者を募集しています。
テキサス内の都市
公式研究テキスト（英語）
Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
- Texas Oncology- Baylor Charles A. Sammons Cancer Center, Dallas
被験者募集中第2/3相
18歳以上 · 全性別 · 2026/09/29更新 · NCT06943755A Phase 3 Study of Ersodetug in Patients With Tumor Hyperinsulinism
- Investigative Site, Houston
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/28更新 · NCT06881992Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors
- University of Texas - MD Anderson Cancer Center, Houston
被験者募集中第1相
24 Months – 18 Years · 全性別 · 2026/09/25更新 · NCT06441331Project: Every Child for Younger Patients With Cancer
- Dell Children's Medical Center of Central Texas, Austin
- Driscoll Children's Hospital, Corpus Christi
- Medical City Dallas Hospital, Dallas
- 他12件
被験者募集中観察研究
25歳以下 · 全性別 · 2026/08/25更新 · NCT02402244A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors
- Crinetics Study Site, Austin
- Crinetics Study Site, Houston
- Crinetics Study Site, Irving
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/07/31更新 · NCT07129252A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
- UT Southwestern Medical Center, Dallas
- MD Anderson Cancer Center, Houston
被験者募集中第1/2相
12歳以上 · 全性別 · 2026/05/27更新 · NCT03093116Peptide Receptor Radionuclide Therapy (PRRT) for the Treatment of Neuroendocrine Tumors
- Clinical Research Institute at Methodist Health System, Dallas
被験者募集中観察研究
18歳以上 · 全性別 · 2026/03/20更新 · NCT04090034Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years
- UT Southwestern Medical Center, Dallas
被験者募集中第4相
18歳〜64歳 · 全性別 · 2026/01/22更新 · NCT04373564A Study of MT-4561 in Patients With Various Advanced Solid Tumors
- The University of Texas MD Anderson Cancer Center, Houston
被験者募集中第1/2相
18歳以上 · 全性別 · 2025/12/11更新 · NCT06943521SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Dallas
- Massive Bio SYNERGY-AI site, Houston
- Massive Bio SYNERGY-AI site, Temple
被験者募集中観察研究
全年齢 · 全性別 · 2025/10/28更新 · NCT03452774A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit
- The University of Texas MD Anderson Cancer Center, Houston
被験者募集中第1相
18歳以上 · 全性別 · 2025/09/23更新 · NCT06805825ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。